CVS stuck to its full-year profit forecasts despite a solid top and bottom line beat in its third quarter earnings report.
posted stronger-than-expected third quarter earnings Wednesday, powered by gains in its pharmacy and health care benefits division, but stuck to its full-year profit forecasts.
Pharmacy & Consumer sales, which were formerly reported in the Retail segment, were up 6% to $28.87 billion,"driven increased prescription volume and brand inflation,' CVS said. Health Care Benefits revenues were up 16.9% to $26.3 billion.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
CVS results top expectations, lifted by strong health services revenueThe results come on the last day of a nationwide walkout by pharmacy staff from CVS, Walgreens and Rite Aid to protest what they call harsh working conditions.
Read more »
CVS Health’s stock up after earnings beat, but company lowers full-year EPS guidanceCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Read more »
CVS results top expectations, lifted by strong health services revenueThe results come on the last day of a nationwide walkout by pharmacy staff from CVS, Walgreens and Rite Aid to protest what they call harsh working conditions.
Read more »
Health services drives CVS through strong third quarterA strong performance from the health services division of CVS on top of cost-cutting pushed third quarter profits and revenue above expectations. While the drug store chain stuck to its adjusted per-share expectations for the year, it lowered guidance for adjusted earnings per share.
Read more »
CVS tops profit estimates amid strength in health services unitCVS tops profit estimates amid strength in health services unit
Read more »
FDA issues warning about certain eye drops from several major brands due to risk of eye infectionThe eye drops were sold under the brands CVS Health, Rite Aid, Target Up&Up, Leader (Cardinal Health), Rugby (Cardinal Health) and Velocity Pharma.
Read more »